EP1539246A4 - INTRODUCTION BY CENTRAL AIRWAYS FOR THE SYSTEMIC ADMINISTRATION OF THERAPEUTIC AGENTS - Google Patents

INTRODUCTION BY CENTRAL AIRWAYS FOR THE SYSTEMIC ADMINISTRATION OF THERAPEUTIC AGENTS

Info

Publication number
EP1539246A4
EP1539246A4 EP03762973A EP03762973A EP1539246A4 EP 1539246 A4 EP1539246 A4 EP 1539246A4 EP 03762973 A EP03762973 A EP 03762973A EP 03762973 A EP03762973 A EP 03762973A EP 1539246 A4 EP1539246 A4 EP 1539246A4
Authority
EP
European Patent Office
Prior art keywords
introduction
therapeutic agents
systemic administration
central airways
airways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762973A
Other languages
German (de)
French (fr)
Other versions
EP1539246A2 (en
Inventor
Richard S Blumberg
Wayne I Lencer
Neil E Simister
Alan J Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Bioverativ Therapeutics Inc
Original Assignee
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/en
Application filed by Brigham and Womens Hospital Inc, Boston Childrens Hospital, Brandeis University, Syntonix Pharmaceuticals Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP1539246A2 publication Critical patent/EP1539246A2/en
Publication of EP1539246A4 publication Critical patent/EP1539246A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP03762973A 2002-07-03 2003-05-09 INTRODUCTION BY CENTRAL AIRWAYS FOR THE SYSTEMIC ADMINISTRATION OF THERAPEUTIC AGENTS Withdrawn EP1539246A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/US02/21335 2002-07-03
PCT/US2002/021335 WO2003077834A2 (en) 2002-03-15 2002-07-03 Central airway administration for systemic delivery of therapeutics
PCT/US2003/014428 WO2004004798A2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics

Publications (2)

Publication Number Publication Date
EP1539246A2 EP1539246A2 (en) 2005-06-15
EP1539246A4 true EP1539246A4 (en) 2007-05-16

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762973A Withdrawn EP1539246A4 (en) 2002-07-03 2003-05-09 INTRODUCTION BY CENTRAL AIRWAYS FOR THE SYSTEMIC ADMINISTRATION OF THERAPEUTIC AGENTS

Country Status (5)

Country Link
EP (1) EP1539246A4 (en)
JP (1) JP2006513139A (en)
AU (1) AU2003232081B2 (en)
CA (1) CA2491129A1 (en)
WO (1) WO2004004798A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (en) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Clotting factor-fc chimeric proteins to treat hemophilia
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2553187A1 (en) 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
CN103172731A (en) 2004-07-15 2013-06-26 赞科股份有限公司 Optimized Fc variants
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (en) 2004-11-12 2012-08-13 Xencor Inc FC VARIATIONS WITH CHANGED BINDING TO FCRN
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP5825756B2 (en) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Optimized antibody targeting CD19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
BRPI0814465B1 (en) 2007-07-26 2021-11-23 Novagen Holding Corporation FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
JP5314033B2 (en) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム Single IFN-beta fused to mutant IgG Fc fragment
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
PL2808343T3 (en) 2007-12-26 2019-11-29 Xencor Inc Fc variants with altered binding to FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2010033736A1 (en) 2008-09-17 2010-03-25 Xencor, Inc. Novel compositons and methods for treating ige-mediated disorders
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN102492039B (en) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 Fully humanized antihuman HER2 monoclonal antibody
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
ES2902689T3 (en) 2014-04-03 2022-03-29 Csl Behring Ag Immunoglobulin nebulization
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
AU2016355563A1 (en) * 2015-11-16 2018-06-21 The Trustees Of The University Of Pennsylvania Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease
CA3026880A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases
KR102467349B1 (en) 2018-10-29 2022-11-16 에프. 호프만-라 로슈 아게 antibody formulation
CA3228786A1 (en) * 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd25 antibody

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004054A1 (en) * 1989-09-19 1991-04-04 Millar Ann Brigid Treatment of ards
WO1991016038A1 (en) * 1990-04-13 1991-10-31 Toray Industries, Inc. Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof
WO1996022024A1 (en) * 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002043660A2 (en) * 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002100387A1 (en) * 2001-06-11 2002-12-19 A+ Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA25590A1 (en) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst ACTIVE AGENT FOR DRY POWDER DELIVERY
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
EP1273306A4 (en) * 2000-03-31 2005-06-22 Kirin Brewery POWDER PREPARATION INTENDED FOR MUCOUS MEMBRANES COMPRISING A POLYMERIC MEDICAMENT HAVING IMPROVED STORAGE STABILITY

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004054A1 (en) * 1989-09-19 1991-04-04 Millar Ann Brigid Treatment of ards
WO1991016038A1 (en) * 1990-04-13 1991-10-31 Toray Industries, Inc. Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof
WO1996022024A1 (en) * 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002043660A2 (en) * 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002100387A1 (en) * 2001-06-11 2002-12-19 A+ Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Also Published As

Publication number Publication date
AU2003232081A1 (en) 2004-01-23
WO2004004798A2 (en) 2004-01-15
WO2004004798A3 (en) 2004-10-14
CA2491129A1 (en) 2004-01-15
JP2006513139A (en) 2006-04-20
EP1539246A2 (en) 2005-06-15
AU2003232081B2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
EP1539246A4 (en) INTRODUCTION BY CENTRAL AIRWAYS FOR THE SYSTEMIC ADMINISTRATION OF THERAPEUTIC AGENTS
ITMI20000312A0 (en) FORMULATIONS CONTAINING AN ANTICHOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE
EP1487992A4 (en) CENTRAL AIRWAY DELIVERY FOR SYSTEMIC DRUG DELIVERY
EP1646276A4 (en) NEBULIZER FOR THE PRODUCTION OF AEROSOL DRUG
NO2020019I1 (en) Maraviroc optionally in the form of a pharmaceutically acceptable salt
EP1191933A4 (en) ADMINISTRATION OF APOMORPHIN BY NASAL
FR17C1027I2 (en) USEFUL LIPOSOMES FOR DRUG DELIVERY
MA27107A1 (en) AEROSOL FORMULATIONS FOR THE PULMONARY ADMINISTRATION OF DRUGS TO PRODUCE A SYSTEMIC EFFECT.
FR2808685B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS
FR2806918B1 (en) CATHETER FOR THE SPECIFIC ADMINISTRATION OF A MEDICINAL PRODUCT
IL162294A0 (en) Formulation & dosage form for the controlled delivery of therapeutic agents
EP1807146A4 (en) COMPOSITION FOR IMPROVING THE EFFICACY OF DRUG DELIVERY
EP1165597A4 (en) BIFUNCTIONAL MOLECULES FOR DELIVERY OF THERAPEUTIC AGENTS
DZ3246A1 (en) HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVE AS ANTI-INFLAMMATORY / ANALGESIC AGENTS
NO20042208L (en) Vaginally administered anti-dysrhythmic agents for the treatment of pelvic pain
NO20014738L (en) Tolperisone-containing pharmaceutical preparation for oral administration
EP1602366A4 (en) TRANSDERMAL STAMP FOR THE ADMINISTRATION OF IONIC DRUGS
EP1293131A4 (en) THERAPEUTIC AGENTS FOR THE THROAT
EP1406493A4 (en) Administration of agents via the pept-2 transporter
EP1667528A4 (en) HIPPOPHAE RHAMNOIDE COMPOSITIONS FOR ANTICANCER THERAPY
ITMI20020773A0 (en) DRUGS FOR THE TREATMENT OF ARTHRITIS
EE200300501A (en) Formulations of imidazotriazinone for nasal administration
FI20000780L (en) Oral dosage form for controlled release of the drug
ITMI20001051A0 (en) FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCHOPULMONARY DISEASES
ITMI20011307A0 (en) DRUGS FOR EPILEPSY

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070417

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20070411BHEP

Ipc: A61K 38/21 20060101ALI20070411BHEP

Ipc: A61K 38/23 20060101ALI20070411BHEP

Ipc: A61K 48/00 20060101AFI20050209BHEP

17Q First examination report despatched

Effective date: 20120125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120605